Hyperfine Research Inc. specializes in developing portable magnetic resonance imaging (MRI) scanners, aimed at making medical imaging more accessible. Founded in 2014 and based in Guilford, Connecticut, the company focuses on general anatomical brain imaging and addresses various medical conditions, including headaches, strokes, non-specific muscle weakness, encephalopathy, spinal cord compressions, diabetic foot disease, and musculoskeletal trauma. Within a year of its establishment, Hyperfine successfully produced its first images, and it has since improved the quality and functionality of its imaging technology. The company’s mission is to democratize healthcare by ensuring that medical imaging is available to people worldwide.
The Medicines for All Institute, operating under the auspices of the Virginia Commonwealth University School of Engineering.
Smart Immune is a clinical-stage biotechnology company focused on developing the next generation of hematopoietic stem cell-based biotherapies to change prognosis and life quality for patients with devastating diseases. The company first cell therapy program is based on T cell progenitors or ProTcellsTM (CD7+/CD34- ; CD5- cells) curative power to enable a short, polyclonal and safe post transplantation immune recovery. This program be completed by integrative developments from targeted conditioning to gene therapy and genome editing enabling clinicians to access new generation treatments for a wide variety of inherited blood disorders and blood cancers.
UW Medicine Health System is headquartered in the United States. UW Medicine Health System operates as a subsidiary of University of Washington.
VisualDx is an award-winning diagnostic clinical decision support system designed to enhance diagnostic accuracy, aid therapeutic decisions, and improve patient safety. VisualDx combines the world's best curated medical image library with a powerful search engine to give clinicians patient-specific answers in seconds. VisualDx is used by more than 2,300 hospitals, clinics and medical schools around the world.
Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company specializing in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to address life-threatening infections. The company's lead candidate, AR-301, is a fully human IgG1 mAb currently undergoing Phase III trials for treating lung infections linked to S. aureus alphatoxin. Additionally, Aridis is developing several other mAb candidates, including AR-105, in Phase II trials for P. aeruginosa infections, and AR-101, which targets hospital-acquired pneumonia caused by P. aeruginosa serotype O11. Other projects include AR-401, in preclinical stages for Acinetobacter baumannii infections, and AR-201, a preclinical IgG1 mAb for respiratory syncytial virus. The company also has AR-501, an anti-infective therapy in Phase I/IIa clinical trials aimed at managing chronic lung infections in cystic fibrosis patients, as well as acute pneumonia in hospital-acquired pneumonia and ventilator-associated pneumonia settings. Founded in 2003, Aridis is headquartered in San Jose, California.
MYDAWA is a new and innovative service that allows anyone buy wide range of high quality medication and wellness products affordably and conveniently from your mobile phone.
Operator of a biopharmaceutical company intended to develop vaccines against infectious diseases. The company offers an end-to-end outsourcing opportunity that includes QC assays, batch records, a full set of documentation and in-person training that helps in contract manufacturing and development services and also provides a fully equipped quality control lab for identity, potency, purity and stability testing, enabling clients to overcome health inequalities and empower people to live healthy lives.
Developer of a pioneering extended durability mRNA (messenger ribonucleic acid) therapeutics, designed to transform ribonucleic acid drug development into a programmable processor. The company's innovative pipeline is dedicated to tackling unmet medical needs in the realms of metabolic, endocrinologic, and infectious diseases by the utilization of proprietary high-throughput AI (Artificial intelligence)-enabled screening platforms, strategically employed to enhance the stability and facilitate its targeted and selective delivery, enabling scientists to have fully-programmable ribonucleic acid molecules with superior durability and specificity.
Ilara Health, founded in 2018 and headquartered in Nairobi, Kenya, focuses on improving healthcare access in peri-urban and rural areas by providing AI-powered diagnostic devices. The company develops miniature diagnostic tools that integrate with a proprietary technology platform, allowing primary care doctors to deliver accurate and affordable diagnostics. By leveraging existing healthcare infrastructure, Ilara Health enables healthcare providers to record patient data through an electronic medical record system, enhancing the accessibility and reliability of diagnostic services. The company aims to transform primary care in underserved regions by making essential healthcare services more efficient and effective.
E25Bio specializes in the development of rapid diagnostic tests for epidemic fever viruses. It is dedicated to preventing severe downstream health outcomes with the use of mobile, fast, real-time reporting to create unprecedented large datasets to guide informed and timely responses for the control of disease spread.
The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Montreal Heart Institute is a specialty hospital dedicated to the development of cardiology.
Immunocore Limited is a biotechnology company specializing in the discovery and development of innovative T cell receptor-based therapeutics aimed at treating cancer, viral diseases, and autoimmune disorders. Founded in 1999 and headquartered in Abingdon, United Kingdom, with an additional office in Conshohocken, the company has developed a proprietary technology platform that enables the engineering of T cell receptors (TCRs) linked to antibody fragments. This expertise has led to the advancement of IMCgp100, a bi-specific immunotherapeutic currently undergoing clinical trials for metastatic melanoma. Immunocore's focus on addressing diseases with significant unmet medical needs underscores its commitment to advancing novel treatment options.
Immunocore Limited is a biotechnology company specializing in the discovery and development of innovative T cell receptor-based therapeutics aimed at treating cancer, viral diseases, and autoimmune disorders. Founded in 1999 and headquartered in Abingdon, United Kingdom, with an additional office in Conshohocken, the company has developed a proprietary technology platform that enables the engineering of T cell receptors (TCRs) linked to antibody fragments. This expertise has led to the advancement of IMCgp100, a bi-specific immunotherapeutic currently undergoing clinical trials for metastatic melanoma. Immunocore's focus on addressing diseases with significant unmet medical needs underscores its commitment to advancing novel treatment options.
Biological Dynamics Inc. is an early-stage company based in San Diego, California, that focuses on developing a proprietary technology platform utilizing AC Electrokinetic technology for the direct and selective capture of large necrotic particles from physiological solutions, including whole blood, serum, and plasma. This innovative platform allows for the rapid extraction of large molecular weight particles that would not naturally settle. The company offers a range of diagnostic solutions, including the TR(ACE) Assay for monitoring treatment response and tumor burden across various cancers, as well as liquid biopsy testing for personalized medicine applications. Additionally, Biological Dynamics provides clinical laboratory services that encompass molecular and next-generation sequencing. Their technology supports various medical needs, including autoimmune disorders, transplant rejection, infectious diseases, and brain injuries, while also aiding in drug development for conditions like Alzheimer's disease. Founded in 2008, Biological Dynamics aims to enhance disease detection and intervention, ultimately improving patient outcomes and reducing healthcare costs.
Macro-Eyes, Inc. is a machine learning company focused on enhancing access to healthcare through its innovative solutions. Its primary product, Sibyl, employs artificial intelligence for intelligent patient scheduling, which has shown a capability to improve patient utilization by 15%, enabling healthcare providers to see more patients without extending clinical hours. This technology is built on extensive research and deployment of AI for clinical decision support at prominent institutions, including Stanford University and major health systems in the United States. The company has garnered support from the Bill & Melinda Gates Foundation to develop a predictive supply chain for health, aimed at optimizing resource allocation at individual health facilities and pharmacies to prevent stock-outs and reduce waste. Additionally, Macro-Eyes is collaborating with the California Primary Care Association to implement Sibyl across 1,800 health facilities, thereby furthering its mission to increase access to life-saving care.
VisualDx is an award-winning diagnostic clinical decision support system designed to enhance diagnostic accuracy, aid therapeutic decisions, and improve patient safety. VisualDx combines the world's best curated medical image library with a powerful search engine to give clinicians patient-specific answers in seconds. VisualDx is used by more than 2,300 hospitals, clinics and medical schools around the world.
VisualDx is an award-winning diagnostic clinical decision support system designed to enhance diagnostic accuracy, aid therapeutic decisions, and improve patient safety. VisualDx combines the world's best curated medical image library with a powerful search engine to give clinicians patient-specific answers in seconds. VisualDx is used by more than 2,300 hospitals, clinics and medical schools around the world.
1mg is a digital consumer healthcare platform based in Gurgaon, Haryana, India, launched in 2015. It aims to make healthcare more accessible, understandable, and affordable for users. The platform allows individuals to find detailed information about medicines prescribed by doctors and purchase them directly. Users can search for medications based on ailments, drug classes, companies, and brands. Additionally, 1mg features a doctor platform designed to help users locate suitable healthcare professionals for their needs. The company also offers a diagnostics service that enhances transparency and cost-effectiveness for lab tests, empowering Indian consumers and caregivers to choose the right healthcare services at competitive prices.
MedinCell S.A. is a pharmaceutical company based in Jacou, France, that specializes in developing long-acting injectable drug delivery systems using its proprietary BEPO technology. This innovative approach employs biocompatible materials to create formulations that allow for controlled and sustained release of active pharmaceutical ingredients. The company is advancing several product candidates, including mdc-IRM, a subcutaneous injection for schizophrenia currently in Phase III trials, and mdc-CWM, an intra-articular injection aimed at treating pain and inflammation. Additionally, MedinCell is exploring various formulations in research, such as mdc-WWM for contraception and mdc-ANG for central nervous system disorders. The firm focuses on optimizing the efficiency and accessibility of medical treatments across different therapeutic areas through its ongoing research and development efforts.
Credence MedSystems, Inc. is a drug delivery and specialty pharmaceutical company based in Menlo Park, California, focused on enhancing the safety of injectable medications for patients and caregivers. The company develops innovative products, including the Companion Staked Needle Syringe, Companion Luer Syringe, and the Epiphany Safety Syringe system, which features a vacuum-triggered, auto-retractable mechanism for safer use. Credence MedSystems aims to simplify the commercialization process for pharmaceutical partners by integrating advanced safety features into existing drug delivery systems without necessitating significant changes to their manufacturing processes. This approach, termed "Innovation Without Change," allows for a more efficient path to market while ensuring that the delivery systems meet high standards of safety and efficacy. The company, formerly known as SafeShot Technologies, Inc., was established in 2011 and has formed a strategic collaboration with SCHOTT AG to further enhance its product offerings.
PT HaloDoc is a digital healthcare platform based in Jakarta, Indonesia, founded in 2016. It connects patients with a network of 19,000 licensed doctors and 1,000 certified partner pharmacies through its services. Users can engage with medical professionals via video calls, voice calls, and chat, facilitating real-time online consultations. The platform also allows patients to order laboratory tests that can be conducted at home and helps them locate nearby hospitals and clinics. Additionally, HaloDoc provides access to licensed medical laboratory services and a medical delivery service known as ApotikAntar, further enhancing the convenience and accessibility of healthcare for its users.
Biological Dynamics Inc. is an early-stage company based in San Diego, California, that focuses on developing a proprietary technology platform utilizing AC Electrokinetic technology for the direct and selective capture of large necrotic particles from physiological solutions, including whole blood, serum, and plasma. This innovative platform allows for the rapid extraction of large molecular weight particles that would not naturally settle. The company offers a range of diagnostic solutions, including the TR(ACE) Assay for monitoring treatment response and tumor burden across various cancers, as well as liquid biopsy testing for personalized medicine applications. Additionally, Biological Dynamics provides clinical laboratory services that encompass molecular and next-generation sequencing. Their technology supports various medical needs, including autoimmune disorders, transplant rejection, infectious diseases, and brain injuries, while also aiding in drug development for conditions like Alzheimer's disease. Founded in 2008, Biological Dynamics aims to enhance disease detection and intervention, ultimately improving patient outcomes and reducing healthcare costs.
Medsaf is a pharmaceutical supply chain company based in Lagos, Nigeria, founded in 2014. It specializes in the delivery of medications, including antacids, antiviral drugs, antineoplastics, and various supplements, to hospitals, pharmacies, clinics, NGOs, and government entities. Medsaf aims to enhance the availability, affordability, and quality of medications in emerging markets through its end-to-end procurement platform. The company utilizes technology to automate and finance medication procurement, integrating logistics, quality control, and financing services. With a focus on data analytics and blockchain, Medsaf provides stakeholders with essential information regarding the movement of medications, ensuring a more efficient supply chain. The company also offers its products online, expanding access to vital healthcare resources.
Provider of courier services intended to provide medication delivery throughout South Africa. The company's services offer accessible alternatives to the health products distribution and supply chain, deliver life-saving prescription medication and more, providing patients with collection and delivery of chronic medication from public health facilities to their homes.
Qloudlab specializes in innovative healthcare solutions, particularly through its development of Sceptre, the world's first touchscreen-based biosensor. This modular platform facilitates a wide range of diagnostic tests, including blood, urine, saliva, and skin analyses, all within a single mobile system. By integrating smartphone technology with healthcare and cloud computing, Qloudlab aims to streamline diagnostics at the Point-of-Care, making testing more accessible and efficient. The company's technology is designed to be cost-effective, enhancing the user experience for both patients and healthcare professionals. Through its advancements, Qloudlab is positioned to transform the diagnostics landscape, ensuring that essential health information is readily available and easily obtainable.
Macro-Eyes, Inc. is a machine learning company focused on enhancing access to healthcare through its innovative solutions. Its primary product, Sibyl, employs artificial intelligence for intelligent patient scheduling, which has shown a capability to improve patient utilization by 15%, enabling healthcare providers to see more patients without extending clinical hours. This technology is built on extensive research and deployment of AI for clinical decision support at prominent institutions, including Stanford University and major health systems in the United States. The company has garnered support from the Bill & Melinda Gates Foundation to develop a predictive supply chain for health, aimed at optimizing resource allocation at individual health facilities and pharmacies to prevent stock-outs and reduce waste. Additionally, Macro-Eyes is collaborating with the California Primary Care Association to implement Sibyl across 1,800 health facilities, thereby furthering its mission to increase access to life-saving care.
Novartis is a Switzerland-based multinational healthcare company that focuses on developing innovative pharmaceuticals and healthcare solutions to meet the evolving needs of patients globally. Their product portfolio includes treatments in key therapeutic areas such as oncology, rare diseases, neuroscience, immunology, respiratory conditions, and cardio-metabolic diseases. The company is also a leader in animal health, creating medicines for pets, farm animals, and farmed fish to enhance their health and welfare. With a commitment to scientific research, Novartis employs a substantial workforce of scientists and engineers dedicated to advancing drug discovery through advanced technologies and high-throughput screening. They aim to address unmet medical needs, demonstrated by their extensive pipeline of new molecular entities targeting various diseases. Novartis operates globally, with the United States being a significant market, and emphasizes responsible practices within its business strategy to improve overall public health.
Macro-Eyes, Inc. is a machine learning company focused on enhancing access to healthcare through its innovative solutions. Its primary product, Sibyl, employs artificial intelligence for intelligent patient scheduling, which has shown a capability to improve patient utilization by 15%, enabling healthcare providers to see more patients without extending clinical hours. This technology is built on extensive research and deployment of AI for clinical decision support at prominent institutions, including Stanford University and major health systems in the United States. The company has garnered support from the Bill & Melinda Gates Foundation to develop a predictive supply chain for health, aimed at optimizing resource allocation at individual health facilities and pharmacies to prevent stock-outs and reduce waste. Additionally, Macro-Eyes is collaborating with the California Primary Care Association to implement Sibyl across 1,800 health facilities, thereby furthering its mission to increase access to life-saving care.
NemoCare is developing the smartest and most comprehensive patient monitoring and management system. It is an innovative, continuous vital sign data acquisition, analysis and prediction engine that combines unobtrusive wireless wearable sensors and networks, analytical algorithms and big data to provide affordable continuous, high resolution monitoring for all newborns in hospital, and at home. We use design thinking principles to build life-saving technologies that will transform the way healthcare is delivered. Our current area of work is in newborn and maternal care.
Immunocore Limited is a biotechnology company specializing in the discovery and development of innovative T cell receptor-based therapeutics aimed at treating cancer, viral diseases, and autoimmune disorders. Founded in 1999 and headquartered in Abingdon, United Kingdom, with an additional office in Conshohocken, the company has developed a proprietary technology platform that enables the engineering of T cell receptors (TCRs) linked to antibody fragments. This expertise has led to the advancement of IMCgp100, a bi-specific immunotherapeutic currently undergoing clinical trials for metastatic melanoma. Immunocore's focus on addressing diseases with significant unmet medical needs underscores its commitment to advancing novel treatment options.
Qloudlab specializes in innovative healthcare solutions, particularly through its development of Sceptre, the world's first touchscreen-based biosensor. This modular platform facilitates a wide range of diagnostic tests, including blood, urine, saliva, and skin analyses, all within a single mobile system. By integrating smartphone technology with healthcare and cloud computing, Qloudlab aims to streamline diagnostics at the Point-of-Care, making testing more accessible and efficient. The company's technology is designed to be cost-effective, enhancing the user experience for both patients and healthcare professionals. Through its advancements, Qloudlab is positioned to transform the diagnostics landscape, ensuring that essential health information is readily available and easily obtainable.
Mologic Ltd. is a diagnostic product developer based in Thurleigh, United Kingdom, founded in 2003. The company specializes in creating innovative solutions for the research market, focusing on areas such as clinical research, diagnostic development, and microbial physiology. Mologic offers a range of products, including lateral flow kits for human Alpha-1 antitrypsin, desmosine ELISA kits for urine assays, and the fMLP assay kit for measuring fMLP in human urine. In addition to its product lineup, Mologic provides services such as assay and reagent development, clinical evaluation studies, and the creation of high-performance antibodies targeting challenging biological entities. The company was established by Paul and Mark Davis, driven by a mission to enhance healthcare and education, thereby improving patient care and quality of life.
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive patient monitoring products. It provides a patient monitoring solution that incorporates a monitor or circuit board and sensors, including both proprietary single-patient use and reusable sensors and cables. The company also offers Masimo Signal Extraction Technology, which provides the capabilities of measure-through motion and low perfusion pulse oximetry to address the primary limitations of conventional pulse oximetry. In addition, it provides remote-alarm/monitoring solutions and software. The company sells its products to end-users through direct sales force and distributors, as well as to original equipment manufacturers and partners to incorporate into their products. Masimo Corporation was founded in 1989 and is headquartered in Irvine, California.
Atomo Diagnostics is an Australian company that specializes in the research, design, development, and manufacturing of medical devices for blood-based rapid testing, applicable for both professional use and self-testing. Founded in 2010 and headquartered in Leichhardt, Australia, the company provides the AtomoRapid RDT platform, which supports various blood-based lateral flow test assays. These devices are utilized in screening for chronic conditions and detecting infectious diseases, including HIV. Atomo Diagnostics focuses on enhancing usability, safety, and accuracy in rapid diagnostic testing by integrating all test components into a streamlined solution, thereby reducing user error rates. The company operates internationally, with a presence in Europe, Asia, Africa, and Central and South America, and is led by a team experienced in commercializing innovative healthcare products. Its commitment to improving user experience distinguishes Atomo Diagnostics in the point-of-care testing market.
Moderna, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2010. It specializes in the development of therapeutics and vaccines utilizing messenger RNA technology, which instructs cells to produce proteins essential for various biological functions. The company's extensive pipeline includes 40 mRNA development candidates targeting a range of therapeutic areas such as infectious diseases, oncology, cardiovascular diseases, and rare genetic disorders. Moderna gained significant recognition with its COVID-19 vaccine, which was authorized for use in the United States in December 2020. The company maintains strategic partnerships with organizations such as AstraZeneca, Merck & Co., and the Bill & Melinda Gates Foundation, enhancing its research capabilities and manufacturing processes. Additionally, it has research collaborations with esteemed institutions like Harvard University.
CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA. The company develops drugs that are based on Messenger RNA (mRNA) as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases.
mRNA programs include novel mRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases (RNActive), molecular therapies designed to trigger the body’s own production of therapeutic proteins (RNArt), and RNA encoded antibodies (RNAntibody). Its most advanced product candidate, CV9104, is being developed in Phase IIb for the treatment of prostate cancer.
CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA. The company develops drugs that are based on Messenger RNA (mRNA) as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases.
mRNA programs include novel mRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases (RNActive), molecular therapies designed to trigger the body’s own production of therapeutic proteins (RNArt), and RNA encoded antibodies (RNAntibody). Its most advanced product candidate, CV9104, is being developed in Phase IIb for the treatment of prostate cancer.
Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is an oral therapy currently in Phase I/IIa clinical trials for the treatment of phenylketonuria. Additionally, Synlogic is developing SYNB1891, an intratumoral synthetic biotic medicine that is undergoing Phase I clinical trials for the treatment of solid tumors and lymphoma. The company is also exploring synthetic biotics for more common conditions, including inflammatory bowel disease and secondary hyperoxaluria. Synlogic has established a collaboration with Ginkgo Bioworks to advance its development of these innovative therapies.
Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. OHSU is the kind of place where the big news doesn't always involve sports, politics, fashion or even weather. The big news is always about health — health care, health education, health-related research. And various organizations and publications that rank American institutions, programs and faculty in a variety of categories have taken note. Nearly one million patient visits each year. Educating thousands of future health care providers. You get the picture. Immerse yourself in more facts and stats than you probably need about Portland's largest employer, Oregon's provider of care to every corner of the state, and one of the nation's top 28 biomedical research institutions. Oregon Health & Science University is the state’s only academic health center. It provides an uncommon array of services from providing the state’s most comprehensive health care, to educating the next generation of clinicians and biomedical researchers, to achieving breakthroughs and innovations.
Zyomyx has a unique expertise in and passion for tackling difficult “outside-the-box” problems. Highly user-friendly, instrument-free point-of-care tests need to be designed with an advanced level of cartridge engineering and reagent stability, and aligned with aggressive cost targets. Zyomyx specializes in exactly these demanding product requirements. Our immediate focus is an advanced, but simple to use and inexpensive CD4 T-cell point-of-care test that will be launched globally and configured to especially meet the demanding specifications for use in low and middle income countries.
YourBio Health is focused on transforming the blood collection process by developing innovative products that simplify diagnostic testing for patients. The company's flagship technology, Touch Activated Phlebotomy (TAP), allows users to collect their own blood painlessly and easily through a single-step process. This advancement not only enhances patient autonomy but also facilitates access to critical diagnostic information, thereby improving healthcare delivery. The On Vivo platform further supports safe and efficient diagnostic testing, making it accessible to a wider audience. By integrating TAP technology with various diagnostic assays and analytical systems, YourBio Health aims to enhance the overall experience for both patients and clinicians in the healthcare landscape. Founded in 2007 and based in Medford, Massachusetts, the company is committed to advancing informed healthcare participation and outcomes.